CSIMarket
 


Arqule Inc  (ARQL)
Other Ticker:  
 

Arqule Inc's Working Capital Ratio

ARQL's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2019, Working Capital Ratio fell to 8.57 above Arqule Inc average.

Within Major Pharmaceutical Preparations industry 147 other companies have achieved higher Working Capital Ratio than Arqule Inc in third quarter 2019. While Working Capital Ratio total ranking in the third quarter 2019 has deteriorated compared to the prior quarter from 318 to 526.

Explain Working Capital Ratio
How much in Current Assets ARQL´s has?
What is the value of ARQL´s Current Liabilities?


ARQL Working Capital Ratio (Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
(Dec 31 2018)
IV. Quarter
(Sep 30 2018)
III. Quarter
Y / Y Current Liabilities Change 33.47 % 67.48 % 74.85 % 49.76 % 38.43 %
Y / Y Current Assets Change 19.26 % 264.82 % 116.29 % 119.01 % 284.7 %
Working Capital Ratio MRQ 8.57 13.04 6.7 7.28 9.6
ARQL's Total Ranking # 526 # 318 # 615 # 581 # 460
Seq. Current Liabilities Change 6.96 % -3.44 % -1.07 % 30.63 % 34.21 %
Seq. Current Assets Change -29.65 % 87.84 % -8.94 % -0.89 % 115.2 %



Working Capital Ratio third quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 148
Healthcare Sector # 216
Overall Market # 526


Working Capital Ratio Statistics
High Average Low
13.04 4.51 1.49
(Jun 30 2019)   (Dec 31 2011)




Financial Statements
Arqule Inc's Current Liabilities $ 15 Millions Visit ARQL's Balance sheet
Arqule Inc's Current Assets $ 128 Millions Visit ARQL's Balance sheet
Source of ARQL's Sales Visit ARQL's Sales by Geography


Cumulative Arqule Inc's Working Capital Ratio

ARQL's Working Capital Ratio for the trailling 12 Months

ARQL Working Capital Ratio

(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
(Dec 31 2018)
IV. Quarter
(Sep 30 2018)
III. Quarter
Y / Y Current Liabilities TTM Growth 33.47 % 67.48 % 74.85 % 49.76 % 38.43 %
Y / Y Current Assets TTM Growth 19.26 % 264.82 % 116.29 % 119.01 % 284.7 %
Working Capital Ratio TTM 8.86 9.09 7.42 7.27 6.67
Total Ranking TTM # 377 # 375 # 486 # 478 # 507
Seq. Current Liabilities TTM Growth 6.96 % -3.44 % -1.07 % 30.63 % 34.21 %
Seq. Current Assets TTM Growth -29.65 % 87.84 % -8.94 % -0.89 % 115.2 %


On the trailing twelve months basis Due to rise in Current Liabilities in the III Quarter 2019 to $14.93 millions, cumulative Working Capital Ratio decreased to 8.86 above the ARQL average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 454 other companies have achieved higher Working Capital Ratio than Arqule Inc. While Working Capital Ratio overall ranking has improved so far to 349, from total ranking during the twelve months ending second quarter 2019 at 4533.

Explain Working Capital Ratio
How much in Current Assets ARQL´s has?
What is the value of ARQL´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 455
Healthcare Sector # 891
Within the Market # 526


trailing twelve months Working Capital Ratio Statistics
High Average Low
8.9 4.57 3.19
(Jun 30 2019)   (Mar 31 2015)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2019, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2019 MRQ Current AssetsSep 30 2019 MRQ Current Liabilities
Ideaya Biosciences Inc   23.22 $ 112.161  Millions$ 4.831  Millions
Phasebio Pharmaceuticals Inc.  22.85 $ 83.369  Millions$ 3.649  Millions
Applied Therapeutics inc   21.94 $ 37.034  Millions$ 1.688  Millions
Cryoport inc   21.85 $ 102.630  Millions$ 4.698  Millions
Satsuma Pharmaceuticals Inc   21.32 $ 126.583  Millions$ 5.938  Millions
Fulcrum Therapeutics Inc   21.04 $ 105.222  Millions$ 5.002  Millions
Xbiotech Inc   20.24 $ 40.911  Millions$ 2.021  Millions
Seres Therapeutics Inc   20.11 $ 89.578  Millions$ 4.455  Millions
Cassava Sciences Inc  20.05 $ 18.189  Millions$ 0.907  Millions
Kura Oncology Inc   19.66 $ 252.948  Millions$ 12.865  Millions
Provention Bio Inc   19.43 $ 96.371  Millions$ 4.960  Millions
Synthorx, Inc.  18.87 $ 157.660  Millions$ 8.357  Millions
Principia Biopharma Inc   18.03 $ 152.362  Millions$ 8.449  Millions
Enanta Pharmaceuticals Inc  17.77 $ 401.848  Millions$ 22.609  Millions
Crinetics Pharmaceuticals Inc   17.18 $ 135.404  Millions$ 7.882  Millions
Dianthus Therapeutics Inc   17.16 $ 165.230  Millions$ 9.629  Millions
Verrica Pharmaceuticals Inc   17.10 $ 74.040  Millions$ 4.330  Millions
Marker Therapeutics inc   16.90 $ 50.484  Millions$ 2.988  Millions
Glycomimetics Inc   16.75 $ 174.849  Millions$ 10.436  Millions
Kezar Life Sciences Inc   16.67 $ 88.803  Millions$ 5.327  Millions
Tricida Inc   16.30 $ 327.088  Millions$ 20.072  Millions
Milestone Pharmaceuticals inc   15.95 $ 140.971  Millions$ 8.836  Millions
Matinas Biopharma Holdings Inc   15.94 $ 34.251  Millions$ 2.149  Millions
Deciphera Pharmaceuticals Inc   15.35 $ 642.295  Millions$ 41.841  Millions
Sienna Biopharmaceuticals, Inc.  15.27 $ 19.731  Millions$ 1.292  Millions
Cnbx Pharmaceuticals Inc   14.95 $ 6.561  Millions$ 0.439  Millions
Global Blood Therapeutics Inc.  14.95 $ 615.803  Millions$ 41.193  Millions
Equillium Inc   14.72 $ 62.909  Millions$ 4.274  Millions
Homology Medicines Inc  14.67 $ 274.079  Millions$ 18.682  Millions
Igc Pharma Inc   14.66 $ 23.900  Millions$ 1.630  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com